Rigvir® In Germany: Mode of Action, Clinical Use, And Cost
Virotherapy is a relatively new mean to beat cancer, but it has gradually become widespread among patients around the globe. The secret of such popularity lies in the mode of action. Virotherapy generally and Rigvir® in particular imply that you get an injection of an oncolytic virus to get rid of malignant cells in your body.
Rigvir® owes its name to the place of its creation – Riga, where a Latvian scientist Aina Muceniece conducted some research to prove the healing effect of ECHO-7 virus onto melanoma patients. The invention was made in 1950-60s, and the next decades were marked with clinical trials and measurements of effectiveness. The results were as follows:
The latest publication on melanoma treatment with virotherapy in Melanoma Research (October 2015) crowns it all with the following:
“An oncolytic, nonpathogenic ECHO-7 virus adapted for melanoma that has not been genetically modified (Rigvir®) is approved and registered for virotherapy, an active and specific immunotherapy, in Latvia since 2004… These results indicate that the patients treated with Rigvir® had a 4.39–6.57-fold lower mortality than those under observation… In conclusion, Rigvir® significantly prolongs survival in early-stage melanoma patients without any side effect”. 
Considering other types of cancer like sarcoma and lung cancer, the recent general conclusion was made in a medical journal called Acta Pathologica, Microbiologica et Immunologica Scandinavica (briefly APMIS):
“All patients started Rigvir® treatment within a few months after being diagnosed and are currently continuing Rigvir® treatment… Using current standard treatments, the survival of patients with the present diagnoses is low. In contrast, the patients described here were diagnosed 3.5, 7.0, and 6.6 years ago, and their condition has improved and been stable for over 1.5, 6.5, and 4 years, respectively. These observations suggest that virotherapy using Rigvir® can successfully be used in long-term treatment of patients with melanoma stage IV M1c, small cell lung cancer stage IIIA, and histiocytic sarcoma stage IV...” 
The full list of cancer types responsive to Rigvir® includes:
- sarcomas: lymphosarcoma, angiosarcoma, leiomyosarcoma, reticulosarcoma, and rhabdomyosarcoma
- colorectal cancer
- pancreatic cancer
- bladder cancer
- prostate cancer
- kidney cancer
- uterine cancer
- breast cancer
- ovarian cancer
- neuroendocrine tumors
You should know that ECHO-7 virus, the heart of Rigvir®, doesn’t cause any other diseases – it is non-pathogenic. In addition, it doesn’t damage the healthy cells, unlike other therapies do. By the way, virotherapy can be used both like the single cancer fighting method, or it can be integrated into chemo or radiotherapy.
Now you may be wondering about the side effects, but body temperature increase up to 37.5°C/99.5°F is the only one recorded. The medicine is considered to be safe, that’s why it was registered in Latvia in 2004. Although only Georgia and Armenia were the next countries to legitimate Rigvir®, doctors from more than 20 states are interested in Rigvir® effectiveness and potential. They complete training courses in Latvia yearly to introduce the drug in their home country.
Where to Get Treatment with Rigvir® in Germany
As an overseas patient, you may be puzzled by which place to choose to undergo Rigvir® treatment. If Mexico is just too far away to travel, you can opt for Germany as a destination for virotherapy. Klinik Marinus am Stein is located in the region of Bavaria. The clinic is located near Munich. There is an international airport, and most flights are from neighbouring European countries. The flight from London normally takes 3 hours, while direction Vienna - Munich is 1-hour flight. There you have access to Rigvir® treatment along with other anticancer therapies. Other than meals, accommodation, and transfers the treatment package normally includes:
- Rigvir® therapy
- Thymus peptide injections
- Mistletoe therapy
- Oxygen and ozone therapy
- Magnetic field therapy
- Selenium and vitamin C
On average such treatment package costs €5,000-6,000 per week.
The medical team at Klinik Marinus am Stein believes the major reason for cancer is the disbalance between the body and soul. That’s why the treatment approach should be holistic and all-embracing. The main driving force of healing is the patient himself while the doctors perform only the supporting functions.
Virotherapy in Germany can be supplemented with other healing methods that Klinik Marinus am Stein offers: acupuncture, physiotherapy (massages and breathing practices), detoxification, etc. Such an approach helps to fight all cancer types with the exception of metastasizing children, and glioblastoma.
The healing process is impossible without cosy accommodation. Therefore, the German clinic offers neatly designed comfortable double and single rooms with basic facilities like bathroom, free Internet access, TV, etc. There is also a library at your disposal!
We understand that you would like to know if you or the one you love can be qualified for the Rigvir® virotherapy as soon as possible. To do that the medical team first needs to perform a free case evaluation based on the following recent medical records of yours:
- blood count including white blood cells
- radiological findings (CT or MRI)
- histopathological findings
- cytological findings
- medical report
Normally, assessing your case would take up to 72 hours from the moment you provide all necessary files.
To learn whether you or someone close to you can be qualified for Rigvir® therapy please fill in the form on the right and we’ll get back to you within 24 hours (but usually in 2 hours if we receive your inquiry during business hours).
List of References
- Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece, Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100.
- “Adapted ECHO-7 Virus RigVir Immunotherapy (oncolytic Virotherapy) Prolongs Survival in Melanoma Patients after Surgical Excision of the Tumour in a Retrospective Study.” Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurgis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina. Melanoma Research: October 2015 - Volume 25 - Issue 5 - p 421–426.
- Alberts, P., E. Olmane, L. Brokāne, Z. Krastiņa, M. Romanovska, K. Kupčs, S. Isajevs, G. Proboka, R. Erdmanis, J. Nazarovs, and D. Venskus, Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS, 2016. 124(10): p. 896-904.